vs

Side-by-side financial comparison of BTCS Inc. (BTCS) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.

BTCS Inc. is the larger business by last-quarter revenue ($7.1M vs $6.5M, roughly 1.1× Prelude Therapeutics Inc). On growth, BTCS Inc. posted the faster year-over-year revenue change (205.5% vs 116.7%).

BTCS vs PRLD — Head-to-Head

Bigger by revenue
BTCS
BTCS
1.1× larger
BTCS
$7.1M
$6.5M
PRLD
Growing faster (revenue YoY)
BTCS
BTCS
+88.8% gap
BTCS
205.5%
116.7%
PRLD

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BTCS
BTCS
PRLD
PRLD
Revenue
$7.1M
$6.5M
Net Profit
$-19.7M
Gross Margin
12.4%
Operating Margin
-314.1%
Net Margin
-303.5%
Revenue YoY
205.5%
116.7%
Net Profit YoY
38.9%
EPS (diluted)
$-1.58
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BTCS
BTCS
PRLD
PRLD
Q4 25
$7.1M
Q3 25
$4.9M
$6.5M
Q2 25
$2.8M
Q1 25
$1.7M
Q4 24
$2.3M
Q3 24
$739.2K
$3.0M
Q2 24
$561.2K
Q1 24
$451.4K
Net Profit
BTCS
BTCS
PRLD
PRLD
Q4 25
Q3 25
$65.6M
$-19.7M
Q2 25
$3.9M
Q1 25
$-17.3M
Q4 24
Q3 24
$-9.0M
$-32.3M
Q2 24
$-6.7M
Q1 24
$12.3M
Gross Margin
BTCS
BTCS
PRLD
PRLD
Q4 25
12.4%
Q3 25
22.0%
Q2 25
-2.9%
Q1 25
7.1%
Q4 24
2.9%
Q3 24
26.5%
Q2 24
69.9%
Q1 24
64.4%
Operating Margin
BTCS
BTCS
PRLD
PRLD
Q4 25
Q3 25
-314.1%
Q2 25
Q1 25
Q4 24
Q3 24
-1145.9%
Q2 24
Q1 24
Net Margin
BTCS
BTCS
PRLD
PRLD
Q4 25
Q3 25
1328.1%
-303.5%
Q2 25
140.0%
Q1 25
-1022.5%
Q4 24
Q3 24
-1223.0%
-1075.7%
Q2 24
-1198.9%
Q1 24
2715.3%
EPS (diluted)
BTCS
BTCS
PRLD
PRLD
Q4 25
$-1.58
Q3 25
$1.30
$-0.26
Q2 25
$0.14
Q1 25
$-0.86
Q4 24
$0.28
Q3 24
$-0.56
$-0.43
Q2 24
$-0.43
Q1 24
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BTCS
BTCS
PRLD
PRLD
Cash + ST InvestmentsLiquidity on hand
$1.5M
$55.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$139.4M
$58.5M
Total Assets
$214.6M
$94.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BTCS
BTCS
PRLD
PRLD
Q4 25
$1.5M
Q3 25
$4.5M
$55.0M
Q2 25
$639.2K
Q1 25
$269.9K
Q4 24
$2.0M
Q3 24
$254.5K
$153.6M
Q2 24
$536.7K
Q1 24
$670.6K
Stockholders' Equity
BTCS
BTCS
PRLD
PRLD
Q4 25
$139.4M
Q3 25
$225.4M
$58.5M
Q2 25
$31.1M
Q1 25
$20.6M
Q4 24
$34.0M
Q3 24
$25.2M
$156.4M
Q2 24
$33.1M
Q1 24
$39.3M
Total Assets
BTCS
BTCS
PRLD
PRLD
Q4 25
$214.6M
Q3 25
$298.9M
$94.8M
Q2 25
$40.8M
Q1 25
$21.0M
Q4 24
$38.2M
Q3 24
$26.5M
$197.2M
Q2 24
$33.8M
Q1 24
$39.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BTCS
BTCS
PRLD
PRLD
Operating Cash FlowLast quarter
$-9.8M
$-19.1M
Free Cash FlowOCF − Capex
$-9.8M
FCF MarginFCF / Revenue
-138.1%
Capex IntensityCapex / Revenue
0.2%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-15.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BTCS
BTCS
PRLD
PRLD
Q4 25
$-9.8M
Q3 25
$-2.8M
$-19.1M
Q2 25
$-1.3M
Q1 25
$-1.9M
Q4 24
$-3.5M
Q3 24
$-695.2K
$-27.3M
Q2 24
$-924.1K
Q1 24
$-769.0K
Free Cash Flow
BTCS
BTCS
PRLD
PRLD
Q4 25
$-9.8M
Q3 25
$-2.8M
Q2 25
$-1.3M
Q1 25
$-1.9M
Q4 24
$-3.5M
Q3 24
$-27.4M
Q2 24
Q1 24
FCF Margin
BTCS
BTCS
PRLD
PRLD
Q4 25
-138.1%
Q3 25
-56.7%
Q2 25
-48.2%
Q1 25
-112.7%
Q4 24
-152.2%
Q3 24
-912.0%
Q2 24
Q1 24
Capex Intensity
BTCS
BTCS
PRLD
PRLD
Q4 25
0.2%
Q3 25
0.1%
0.0%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
2.1%
Q2 24
Q1 24
Cash Conversion
BTCS
BTCS
PRLD
PRLD
Q4 25
Q3 25
-0.04×
Q2 25
-0.34×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BTCS
BTCS

Builder Plus$5.9M83%
Other$1.2M17%

PRLD
PRLD

Segment breakdown not available.

Related Comparisons